Equity Overview
Price & Market Data
Price: $0.0₃5
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $9,491
Volume: 0
Performance Metrics
1 Week: -75.00%
1 Month: 66.67%
3 Months: %
6 Months: 66.67%
1 Year: -16.67%
YTD: %
Details
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.